Condition
Haemophagocytic Lymphohistiocytosis
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05762640Phase 2RecruitingPrimary
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
NCT05702502Recruiting
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
NCT06734624Not Yet Recruiting
The Microbiome in Blood Cancer and HLH
Showing all 3 trials